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We have examined a series of 37 patients
with histologically proved primary malignant
melanoma for evidence of tumour-directed
cellular immunity. Using the leucocyte
migration technique we found evidence of
such reactivity in 24/37 patients. Tests
with control donors' leucocytes and control
antigen preparations supported the specificity
of the reaction. The histology of all
tumours was carefully analysed using new
criteria (Classification of Melanoma, Sydney
1972. Cancer, N.Y., 1972 [in press]) for
histological analysis of malignant melanoma.
Histological and immunological findings for
each patient were collated. Evidence of
immune reactivity was most frequently
associated with superficial tumours; tumours
showing microscopic evidence of lymphatic
invasion, non-ulcerated tumours showing a
heavy peritumoral infiltrate of lymphocytes
and plasma cells.
FLUORESCENT ANTIBODY STUDIES
IN MALIGNANT MELANOMA. R. H.
WHITEHEAD and L. E. HUGHES. University
Department of Surgery, Welsh National
School ofMedicine, Cardiff.
There have been a number of reports
describing antibody to melanoma in approxi-
mately 60% of patients with melanoma.
However, the technique and the site of
fluorescence within the cell have varied.
Sera from melanoma patients were tested
against 6 melanoma cell lines by immuno-
fluorescence using cell smears. Results were
analysed with regard to the pathological
classification of the patients' tumour. No
immunofluorescence was detected with sera
from patients presenting with tumour re-
stricted to the upper dermis, whereas up to
40% of patients wth tumour spread to the
lower dermis were positive. Sera from
patients with secondary melanoma showed a
higher reactivity.
The cell lines varied in antigenicity and
the lines which were most antigenic were also
most reactive against normal sera.
Ifthe results were analysed with regard to
the number of sera reacting against at least
one cell line, then 50% ofprimary melanoma
sera and 90% of secondary melanoma sera
were positive.
This indicates that the method ofanalysis
is crucial to the final result, and the current
status of serum immunity to melanoma is
discussed in this context.
ASSESSMENT OF LYMPHOCYTE
TRANSFORMATION IN THE
PATIENT PRESENTING WITH
HODGKIN'S DISEASE. P. M. DENTON
and E. M. STANLEY. Radiotherapy Re-
search Unit, Royal Marsden Hospital, Sutton.
Surrey.
There has been much discussion as to
whether Hodgkin's disease reflects a state of
impaired lymphocyte function. That the
disease seems to be characterized by the early
onset of immunological derangement with
regard to cell mediated immunity gives some
support to this tenet. Recently, however,
the percentage of Hodgkin's disease patients
showing early anergy has been questioned.
A closer look at the lymphocytes in Hodgkin's
disease and their ability to initiate an
immune response seemed to be indicated.
A longitudinal study has commenced to
investigate the variable ability of peripheral
blood lymphocytes from Hodgkin's disease
patients to transform, under stimulation by
the one-way mixed lymphocyte reaction,
from the time of presentation through the
course of their disease.
Preliminary observations indicate that
the degree of lymphocyte transformation in
the untreated Hodgkin's disease patient does
not show any correlation with the age, sex,
clinical stage, histology or presence of
systemic symptoms. The degree of stimula-
tion has been found to be independent of the
absolute lymphocyte count.
Commencement of radiotherapy abolishes
lymphocyte transformation and its effects
are prolonged. The effect of chemotherapy
is less severe.
LYMPHOCYTE TRANSFORMATION
IN LARGE BOWEL CANCER. I.
LAUDER. Department of Pathology, Royal
Victoria Infirmary, Newcastle upon Tyne,
and G. BONE, Department of Surgery,
University ofNewcastle upon Tyne.
Controversy still exists as to whether
lymphocyte transformation to phytohaemag-
glutinin (PHA) is depressed in patients with
non-lymphoid malignancies. The need to
determine dose response curves in any patient
with suspected immune deficiency has